BioMark Diagnostics(DE:20B)
€0.260.00 (-0.76%)
DE:20B
BioMark Diagnostics financials statements
€0.26
At close:0.00 (-0.76%)
BioMark Diagnostics (20B) Ratios
5 Followers
BioMark Diagnostics Ratios
DE:20B's free cash flow for Q4 2026 was C$504.22K. For the 2026 fiscal year, DE:20B's free cash flow was increased by C$623.91K and operating cash flow was C$-119.69K. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.99 | 2.14 | 0.16 | 0.33 | 1.00 |
| Quick Ratio | 0.99 | 2.14 | 0.16 | 0.33 | 1.00 |
| Cash Ratio | 0.56 | 2.01 | 0.13 | 0.25 | 0.95 |
| Solvency Ratio | -0.72 | -1.10 | -0.61 | -0.60 | -1.05 |
| Operating Cash Flow Ratio | -0.99 | -0.89 | -0.79 | -0.80 | -0.49 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -1.33 | -8.36 | 0.00 |
| Net Current Asset Value | C$ -445.38K | C$ 1.25M | C$ -1.50M | C$ -1.61M | C$ -109.02K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.39 | 0.14 | 1.42 | 0.71 | 0.13 |
| Debt-to-Equity Ratio | 2.19 | 0.26 | -2.54 | -1.65 | -1.51 |
| Debt-to-Capital Ratio | 0.69 | 0.21 | 1.65 | 2.54 | 2.97 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | -0.18 | 7.32 |
| Financial Leverage Ratio | 5.62 | 1.80 | -1.79 | -2.31 | -12.05 |
| Debt Service Coverage Ratio | -21.55 | -23.80 | -1.07 | -6.58 | -260.12 |
| Interest Coverage Ratio | -29.59 | -31.01 | -11.43 | -25.84 | -264.28 |
| Debt to Market Cap | 0.00 | 0.00 | 0.03 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.02 | 0.02 | 0.00 |
| Net Debt to EBITDA | -0.07 | 1.38 | -1.51 | -0.54 | 0.70 |
| Profitability Margins | |||||
| Gross Profit Margin | -539.40% | 100.00% | 100.00% | 100.00% | 0.00% |
| EBIT Margin | -3130.74% | -1209.82% | -803.96% | -3196.28% | 0.00% |
| EBITDA Margin | -2491.34% | -949.62% | -563.07% | -2787.41% | 0.00% |
| Operating Profit Margin | -3130.74% | -1237.31% | -806.71% | -2922.50% | 0.00% |
| Pretax Profit Margin | -2681.89% | -1249.73% | -874.52% | -3309.36% | 0.00% |
| Net Profit Margin | -2470.76% | -1249.73% | -874.52% | -3309.36% | 0.00% |
| Continuous Operations Profit Margin | -2470.76% | -1249.73% | -874.52% | -3309.36% | 0.00% |
| Net Income Per EBT | 92.13% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 85.66% | 101.00% | 108.40% | 113.24% | 100.05% |
| Return on Assets (ROA) | -79.40% | -61.49% | -131.08% | -98.80% | -114.82% |
| Return on Equity (ROE) | -446.20% | -110.70% | 234.15% | 228.71% | 1383.40% |
| Return on Capital Employed (ROCE) | -245.47% | -100.34% | 847.04% | 4328.72% | -3582.96% |
| Return on Invested Capital (ROIC) | -163.31% | -86.93% | -140.65% | -310.35% | -2718.34% |
| Return on Tangible Assets | -79.40% | -61.49% | -131.08% | -98.80% | -114.82% |
| Earnings Yield | -2.47% | -8.37% | -5.58% | -8.74% | -3.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.19 | 0.96 | 3.79 | 0.53 | 0.00 |
| Payables Turnover | 3.80 | 0.00 | 0.00 | 0.00 | 0.50 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.08 | 0.34 | 0.19 | 0.05 | 0.00 |
| Asset Turnover | 0.03 | 0.05 | 0.15 | 0.03 | 0.00 |
| Working Capital Turnover Ratio | 0.09 | 0.84 | -0.13 | -0.09 | 0.00 |
| Cash Conversion Cycle | 211.03 | 380.26 | 96.22 | 682.34 | -723.39 |
| Days of Sales Outstanding | 307.19 | 380.26 | 96.22 | 682.34 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 96.17 | 0.00 | 0.00 | 0.00 | 723.39 |
| Operating Cycle | 307.19 | 380.26 | 96.22 | 682.34 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | -257.40 | -309.40 | -223.61 | -20.34 | 0.00 |
| Capital Expenditure Coverage Ratio | -257.40 | -309.40 | -223.61 | -20.34 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.50 | -2.41 | -0.64 | -1.15 | -3.82 |
| Operating Cash Flow to Sales Ratio | -18.21 | -7.09 | -6.02 | -27.40 | 0.00 |
| Free Cash Flow Yield | -1.82% | -4.77% | -3.86% | -7.59% | -1.48% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -40.43 | -11.95 | -17.91 | -11.44 | -28.14 |
| Price-to-Sales (P/S) Ratio | 1001.91 | 149.23 | 156.67 | 378.58 | 0.00 |
| Price-to-Book (P/B) Ratio | 180.94 | 13.22 | -41.95 | -26.16 | -389.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -54.80 | -20.99 | -25.91 | -13.17 | -67.58 |
| Price-to-Operating Cash Flow Ratio | -55.02 | -21.05 | -26.03 | -13.81 | -67.58 |
| Price-to-Earnings Growth (PEG) Ratio | 1.07 | -0.34 | 0.71 | -0.33 | 2.28 |
| Enterprise Value Multiple | -40.29 | -14.33 | -29.34 | -14.13 | -27.90 |
| Enterprise Value | 60.01M | 20.99M | 26.96M | 17.30M | 30.03M |
| EV to EBITDA | -40.29 | -14.33 | -29.34 | -14.13 | -27.90 |
| EV to Sales | 1003.68 | 136.09 | 165.18 | 393.76 | 0.00 |
| EV to Free Cash Flow | -54.90 | -19.14 | -27.32 | -13.70 | -65.92 |
| EV to Operating Cash Flow | -55.11 | -19.20 | -27.44 | -14.37 | -65.92 |
| Tangible Book Value Per Share | 0.00 | 0.02 | -0.01 | -0.01 | -0.00 |
| Shareholders’ Equity Per Share | 0.00 | 0.02 | -0.01 | -0.01 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | 0.00 | 0.00 | -0.03 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 |
| Tax Burden | 0.92 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.86 | 1.03 | 1.09 | 1.04 | 1.00 |
| Research & Development to Revenue | 11.17 | 4.51 | 3.99 | 11.33 | 0.00 |
| SG&A to Revenue | 14.74 | 6.48 | 4.44 | 19.66 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 2.38 | 0.46 | 0.00 | 0.00 |
| Income Quality | 0.74 | 0.57 | 0.69 | 0.83 | 0.42 |
Currency in CAD
